FGFR inhibitors

HLB will launch its newly approved bile-duct drug alone into a US segment worth at most $81 million

HLB's US unit Elevar won FDA approval for Rifiktu 21 months after licensing it from Relay Therapeutics, a first for a Korean company filing directly. Elevar will sell the bile-duct cancer drug without a partner from the fourth quarter, in a second-line niche worth roughly $81 million a year at most.